Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats

Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada.

OBJECTIVES: The present study sought to evaluate the effects of the afterload-reducing drugs captopril and prazosin on changes in antioxidants as well as oxidative stress in relation to hemodynamic function in congestive heart failure (CHF) subsequent to myocardial infarction (MI). BACKGROUND: Afterload reduction therapy has been shown to reduce morbidity and mortality in patients with MI. CHF subsequent to MI in rats is associated with a decrease in myocardial endogenous antioxidants and an increase in oxidative stress. METHODS: The left anterior descending coronary artery in male Sprague-Dawley rats was ligated. Sham and experimental (post-MI [PMI]) animals were assessed for hemodynamic function as well as lung and liver weights at 1, 4 and 16 weeks after operation. At 4 weeks, some rats were also treated with captopril (2 g/liter in drinking water daily) or prazosin (0.2 mg/kg body weight subcutaneously daily) and assessed at 16 weeks. Hearts were isolated to study the activity of superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and catalase as well as for thiobarbituric acid reactive substances (TBARS). RESULTS: CHF at 4 and 16 weeks in the infarcted rats was indicated by an increase in left ventricular end-diastolic pressure and wet/dry weight lung and liver ratios and depressed left ventricular systolic pressure and dyspnea. All these changes were attenuated in both the captopril- and prazosin-treated groups. SOD, GSHPx and catalase activity in the untreated PMI groups was decreased at 4 and 16 weeks. However, treatment with captopril resulted in a significant improvement in SOD, GSHPx and catalase activity in the 16-week PMI group. With prazosin, only SOD activity was improved in the treated 16-week PMI group. Lipid peroxidation as indicated by TBARS was significantly increased in the 16-week PMI group, and both captopril and prazosin modulated this increase. CONCLUSIONS: Occurrence of an antioxidant deficit and an increase in oxidative stress in the myocardium may play a role in the pathogenesis of CHF subsequent to MI. Attenuation of these changes in antioxidant activity with vasodilator (or antioxidant?) therapy mitigates the process of heart failure.

This article has been cited by other articles:

				Q. Shao, B. Ren, V. Elimban, P. S. Tappia, N. Takeda, and N. S. Dhalla Modification of sarcolemmal Na+-K+-ATPase and Na+/Ca2+ exchanger expression in heart failure by blockade of renin-angiotensin system Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2637 - H2646. [Abstract] [Full Text] [PDF]

				C. A. Everson, C. D. Laatsch, and N. Hogg Antioxidant defense responses to sleep loss and sleep recovery Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2005; 288(2): R374 - R383. [Abstract] [Full Text] [PDF]

				L. G. Bongartz, M. J. Cramer, P. A. Doevendans, J. A. Joles, and B. Braam The severe cardiorenal syndrome: 'Guyton revisited' Eur. Heart J., January 1, 2005; 26(1): 11 - 17. [Abstract] [Full Text] [PDF]

				L. Gao, W. Wang, Y.-L. Li, H. D. Schultz, D. Liu, K. G. Cornish, and I. H. Zucker Superoxide Mediates Sympathoexcitation in Heart Failure: Roles of Angiotensin II and NAD(P)H Oxidase Circ. Res., October 29, 2004; 95(9): 937 - 944. [Abstract] [Full Text] [PDF]

				N. Khaper and P. K. Singal Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1461 - 1466. [Abstract] [Full Text] [PDF]

				H. Tsutsui, T. Ide, S. Hayashidani, N. Suematsu, H. Utsumi, R. Nakamura, K. Egashira, and A. Takeshita Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury Cardiovasc Res, January 1, 2001; 49(1): 103 - 109. [Abstract] [Full Text] [PDF]

				H. J. Oskarsson, L. Coppey, R. M. Weiss, and W.-G. Li Antioxidants attenuate myocyte apoptosis in the remote non-infarcted myocardium following large myocardial infarction Cardiovasc Res, February 1, 2000; 45(3): 679 - 687. [Abstract] [Full Text] [PDF]

				S. Dieterich, U. Bieligk, K. Beulich, G. Hasenfuss, and J. Prestle Gene Expression of Antioxidative Enzymes in the Human Heart : Increased Expression of Catalase in the End-Stage Failing Heart Circulation, January 4, 2000; 101(1): 33 - 39. [Abstract] [Full Text] [PDF]

				G. Kojda and D. Harrison Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure Cardiovasc Res, August 15, 1999; 43(3): 652 - 671. [Full Text] [PDF]

				E. Coodley Newer Drug Therapy for Congestive Heart Failure Arch Intern Med, June 14, 1999; 159(11): 1177 - 1183. [Abstract] [Full Text] [PDF]

				P. K Singal, N. Khaper, V. Palace, and D. Kumar The role of oxidative stress in the genesis of heart disease Cardiovasc Res, December 1, 1998; 40(3): 426 - 432. [Abstract] [Full Text] [PDF]

				T. Shimada, M. Yoshiyama, K. Takeuchi, T. Omura, Y. Takemoto, S. Kim, H. Iwao, and J. Yoshikawa Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats Cardiovasc Res, March 1, 1998; 37(3): 618 - 626. [Abstract] [Full Text] [PDF]

				M. F. Hill and P. K. Singal Right and Left Myocardial Antioxidant Responses During Heart Failure Subsequent to Myocardial Infarction Circulation, October 7, 1997; 96(7): 2414 - 2420. [Abstract] [Full Text]